CO2022001164A2 - Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn - Google Patents

Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn

Info

Publication number
CO2022001164A2
CO2022001164A2 CONC2022/0001164A CO2022001164A CO2022001164A2 CO 2022001164 A2 CO2022001164 A2 CO 2022001164A2 CO 2022001164 A CO2022001164 A CO 2022001164A CO 2022001164 A2 CO2022001164 A2 CO 2022001164A2
Authority
CO
Colombia
Prior art keywords
methods
antibody
present disclosure
frnf
antagonists
Prior art date
Application number
CONC2022/0001164A
Other languages
English (en)
Spanish (es)
Inventor
Brian Mackness
Huawei Qiu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CO2022001164A2 publication Critical patent/CO2022001164A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2022/0001164A 2019-07-25 2022-02-04 Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn CO2022001164A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists

Publications (1)

Publication Number Publication Date
CO2022001164A2 true CO2022001164A2 (es) 2022-03-08

Family

ID=72087159

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001164A CO2022001164A2 (es) 2019-07-25 2022-02-04 Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn

Country Status (13)

Country Link
US (1) US12655200B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004039A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022542884A (cg-RX-API-DMAC7.html)
KR (1) KR20220038432A (cg-RX-API-DMAC7.html)
CN (2) CN114466663B (cg-RX-API-DMAC7.html)
AU (1) AU2020315925A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001255A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148764A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001164A2 (cg-RX-API-DMAC7.html)
IL (1) IL290101A (cg-RX-API-DMAC7.html)
MX (1) MX2022001038A (cg-RX-API-DMAC7.html)
TW (1) TW202120539A (cg-RX-API-DMAC7.html)
WO (1) WO2021016571A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
TW202525845A (zh) 2023-08-23 2025-07-01 法商賽諾菲公司 基於ctla—4之溶體降解劑及其用途
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
IL328245A (en) 2023-11-08 2026-07-01 Sanofi Sa CD25-based lysosomal compartment and its uses
AU2024413168A1 (en) * 2023-12-27 2026-07-16 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE
WO2026133288A2 (en) 2024-12-20 2026-06-25 Sanofi IL-2RβΥ BASED LYSOSOMAL DEGRADER AND USES THEREOF
WO2026133294A1 (en) 2024-12-20 2026-06-25 Sanofi Pd-1/gitr multispecific binding polypeptides and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション,インコーポレイテッド Fc領域変異体
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) * 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2013011366A (es) * 2011-03-30 2014-05-12 Chugai Pharmaceutical Co Ltd Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad.
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
US20170211876A1 (en) 2014-06-12 2017-07-27 Hoffmann-La Roche Inc. Method for selecting antibodies with modified fcrn interaction
RU2713131C1 (ru) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
MX386491B (es) * 2015-03-09 2025-03-18 argenx BV Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
CA3022547A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
WO2018213097A1 (en) * 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020015006A2 (pt) * 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada

Also Published As

Publication number Publication date
JP2025098167A (ja) 2025-07-01
IL290101A (en) 2022-03-01
EP4004039A2 (en) 2022-06-01
TW202120539A (zh) 2021-06-01
CN114466663A (zh) 2022-05-10
US20210024620A1 (en) 2021-01-28
US12655200B2 (en) 2026-06-16
WO2021016571A3 (en) 2021-03-04
KR20220038432A (ko) 2022-03-28
JP2022542884A (ja) 2022-10-07
CA3148764A1 (en) 2021-01-28
CN114466663B (zh) 2026-01-02
WO2021016571A2 (en) 2021-01-28
CN122272792A (zh) 2026-06-26
AU2020315925A1 (en) 2022-03-03
BR112022001255A2 (pt) 2022-06-14
MX2022001038A (es) 2022-04-26

Similar Documents

Publication Publication Date Title
MX2022001038A (es) Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn.
BR112021014074A2 (pt) Proteínas de ligação ao antígeno anti-receptor il2 gama
Ramanathan et al. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination
MX2022003466A (es) Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap).
CR20210057A (es) Anticuerpos anti-sortilina y métodos para su uso
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
WO2021055253A3 (en) Anti-tnfr2 antibodies and methods of use
CL2021001230A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
BR112012007365A2 (pt) proteínas de ligação à il-1
EA201170158A1 (ru) Агенты, связывающиеся с рецептором notch1, и способы их применения
RU2015104760A (ru) Связывающие kir3dl2 агенты
MX386491B (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
BRPI0621800B8 (pt) anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo
JOP20210169B1 (ar) أجسام مضادة أحادية النسيلة ضد منطقة سلسلة بيتا من trbv9 بشري
EA202100199A1 (ru) Моноклональные антитела, специфически связывающиеся с trbv-9 человека
KR20200119344A (ko) 인간 백혈병 억제 인자 (lif)를 인식하는 항체, 및 원치않는 세포 증식과 관련된 질환 치료에서 항-lif 항체의 용도
WO2021048564A3 (en) Antigen-binding domain
CO2022011195A2 (es) Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia génica y para eliminar o reducir inmunoglobulinas
MX2021012335A (es) Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
RU2016141144A (ru) Способ супрессии злокачественной опухоли посредством ингибирования тмсс3
EP4613334A3 (en) Her-2 binding antibodies
MX2024008933A (es) Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.
CL2025002824A1 (es) Nueva molécula de unión
PH12019550203A1 (en) Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
BR112022009638A2 (pt) Composições e métodos para o tratamento de doenças mediadas por ccr9 usando inibidor de ccr9 e anticorpos de bloqueio anti-tnf-alfa